IP Library Granted Patent US 8,785,490
Granted Patent B2
US 8,785,490 · App. 13/639,864 · Granted Jul 22, 2014

Compounds for treating disease, for administering, and for pharmaceutical compositions

Inventors: John O. Trent (Louisville, KY); Jason B. Meier (Louisville, KY); Kelby B. Napier (St. Louis, MO)
Assignee: University of Louisville Research Foundation, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,785,490
App. No.
13/639,864
Granted
Jul 22, 2014
Kind
B2
Abstract

Some embodiments of this invention include methods for treating disease and methods for administering a compound of Formula (I). In some aspects of the invention, diseases can be treated by administration of compositions comprising a compound of Formula (I). Pharmaceutical compositions of some embodiments of the present invention comprise a compound of Formula (I).

Claims (22)

1. A method for treating a CXCR4 expressing cancer in an animal comprising

administering a composition comprising a compound of Formula (I) to the animal,

wherein the CXCR4 expressing cancer is breast cancer, ovarian cancer, colon cancer, melanoma, squamous cell carcinoma, chronic lymphocytic leukemia, rectal cancer, lung cancer, or prostate cancer, and

the compound of Formula (I) is selected from the group consisting of

2. The method of claim 1 , further comprising identifying an animal with the CXCR4 expressing cancer.

3. The method of claim 1 , wherein the compound is selected from the group consisting of I-38, I-47 to I-52, and I-54 to I-58.

4. The method of claim 1 , wherein the CXCR4 expressing cancer comprises a cancerous tumor.

5. The method of claim 1 , wherein the CXCR4 expressing cancer comprises a cancerous tumor and the treating results in a decrease in the size of the cancerous tumor.

6. The method of claim 1 , wherein the CXCR4 expressing cancer comprises a cancerous tumor and the treating results in a decrease in the number of cancerous tumors.

7. The method of claim 1 , wherein the CXCR4 expressing cancer is metastasized.

8. The method of claim 1 , wherein the CXCR4 expressing cancer is metastasized to the breasts, ovaries, colon, rectum, lungs, or prostate.

9. The method of claim 1 , wherein the CXCR4 expressing cancer is breast cancer or lung cancer.

10. The method of claim 1 , wherein the administering is part of an adjuvant treatment.

11. The method of claim 1 , wherein the compound of Formula (I) inhibits chemotaxis.

12. The method of claim 1 , wherein the compound of Formula (I) inhibits intracellular calcium mobilization.

13. The method of claim 1 , wherein the treating results in at least one of modulation of tumor cell migration or modulation of homing of the neoplastic cells.

14. The method of claim 1 , wherein the compound of Formula (I) modulates activity of CXCR4.

15. The method of claim 1 , wherein the animal is a mammal.

16. The method of claim 1 , wherein the animal is a human.

17. The method of claim 1 , wherein the administering is by an oral route or by a parenteral route.

18. The method of claim 1 , wherein the treating comprises treating metastasis of breast cancer, ovarian cancer, colon cancer, melanoma, chronic lymphocytic leukemia, rectal cancer, lung cancer, or prostate cancer.

19. The method of claim 1 , wherein the compound of Formula (I) is I-38.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2014
From: TRENT, JOHN O, MR.; MEIER, JASON B, MR.; NAPIER, KELBY B., MR.
To: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
Reel/Frame 032631/0581 →
CONFIRMATORY LICENSE Recorded Dec 4, 2012
From: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
To: US ARMY, SECRETARY OF THE ARMY
Reel/Frame 029400/0249 →
Continuity (2)
Provisional Application 61322485 · Apr 9, 2010
Related Publication 20130059852A1 · Mar 7, 2013